01.03.2010 • NewsSolutiaSolarMergers & Acquisitions (M&A)

Solutia to Buy Etimex Solar for $326 Million

U.S. specialty chemicals maker Solutia is set to buy closely held Etimex Solar, a maker of chemicals used in solar panels, for $326 million in cash, Wall Street Journal said. The deal is set to be announced on Monday, according to the paper.

Etimex Solar, a division of German plastics firm Etimex Holdings, makes a film that covers and weatherizes solar panels, the paper said. Solutia will look for a new financing package to help fund the Etimex deal. The firm may tap the high-yield market to raise new capital, the paper said.

Etimex had 2009 annual sales of around $67 million and earnings of $34 million, according to Solutia, the paper said. The Etimex deal would help Solutia, as majority of the company's $1.7 billion in annual sales currently come from the weak U.S. auto and construction industries, the daily said.

Solutia and Etimex Solar could not be immediately reached for comment by Reuters.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.